From John Money to Modern Gender Clinics: An Insider Speaks - Dr. Quentin Van Meter (#28)
11 August 2025
With Dr. Quentin Van Meter
North America
Dr. Quentin Van Meter trained alongside John Money at Johns Hopkins and spent four decades watching gender medicine evolve from fringe experimentation to mainstream clinical practice. His account of WPATH's abandonment of scientific standards, the near-universal progression from puberty blockers to cross-sex hormones, and the fabrication of AAP policy aligns closely with the evidentiary failures the Cass Review identified in NHS England's own practice. This episode offers rare clinical depth to debates that have reshaped UK paediatric care.
Dr. Quentin Van Meter brings to this conversation something rare: more than four decades of front-line paediatric endocrinology, including a formative period training at Johns Hopkins under John Money in the era when gender medicine was still an experimental fringe. Money, whose theories on gender identity emerged from deeply flawed and ethically compromised research, is now widely recognised as having laid foundations that later became clinical orthodoxy. Van Meter's firsthand account of that environment — including Money's readiness to subject a child with normal testosterone to surgical intervention — is not anecdote but clinical testimony from a witness to the origins of a contested field. When Van Meter treated his first gender-distressed child in 1993, no clinical guidelines existed. What followed was not the gradual accumulation of rigorous evidence but the consolidation of ideology into institutional policy. He describes WPATH, the body whose standards of care were adopted internationally and whose guidelines shaped NHS England's own gender service protocols for years, as having abandoned scientific rigour in favour of advocacy. The Cass Review, published in April 2024, reached broadly compatible conclusions: that the evidence base underpinning WPATH's standards was of poor quality, and that NHS England had been operating without the independent research foundation that sound clinical governance requires. The specific claims Van Meter makes about puberty blockers deserve particular scrutiny in the UK context. He cites a figure of 98 per cent of children who receive puberty blockers subsequently proceeding to cross-sex hormones — a finding consistent with the persistence data that troubled the Cass Review and contributed directly to NHS England's decision to end the routine prescription of puberty blockers for gender dysphoria outside of approved research settings. He also raises the question of long-term cognitive effects, an area where Cass similarly found the evidence to be inadequate and where NHS-linked research trials are now attempting to generate the data that should have preceded widespread clinical use. Van Meter's departure from the American Academy of Pediatrics after 37 years, on the grounds that its transgender policy was not grounded in evidence, mirrors a pattern visible in the UK: professional bodies endorsing clinical approaches that their own most experienced members regard as scientifically unsupported. The RCPCH and NHS England have since moved considerably from positions held only a few years ago, not because social attitudes shifted but because the evidence review that should always have happened finally did. The value of this episode lies in the historical depth Van Meter provides. Policy arguments about what should happen in paediatric gender medicine often lack the clinical memory of how current practice came to exist. Understanding that the affirmative model did not emerge from controlled trials but from contested theories developed by a single researcher at a single American institution — and subsequently institutionalised through advocacy rather than peer-reviewed evidence — is essential context for evaluating both where the UK has been and where it is now heading.
